On 14 October 2026, Galderma announced that it had signed an agreement to acquire ZO Skin Health, a US skincare brand distributed through physicians, medical spas and online. According to the group’s press release, the deal covers 100% of the company at an enterprise value of USD 1.5 billion, paid in cash and funded through existing cash and bank financing. The sellers are shareholders that include funds managed by Blackstone Tactical Opportunities and the Obagi family, named after the dermatologist who founded the brand in 2007, according to the press release Blackstone issued when it took a majority stake in 2020. Closing is expected in the fourth quarter of 2026 or early 2027, subject to regulatory approvals and customary conditions.<\/p>\n
Also according to Galderma, ZO generated net sales of about USD 330 million over the twelve months ended June 2026. Its range includes more than 40 products, distributed through more than 16,500 accounts (physicians, medical spas and online sales combined) across more than 40 countries. The group explains that ZO’s daily routines, built around retinol and acids, complement Alastin, the peptide brand it already owns, which mainly supports pre- and post-procedure care. Galderma expects the deal to be neutral to its core earnings per share in the first full year after closing, and to slightly dilute its core EBITDA margin in 2027.<\/p>\n
For an executive discovering this segment, a definition is needed. Physician-dispensed skincare<\/strong> refers to cosmetic products that a practitioner recommends, sells or hands to a patient or client, most often as a follow-up to a procedure or a care plan, rather than leaving them to be chosen alone in front of a shelf or a screen. The USD 330 million figure shows that a channel often seen as niche can carry a brand with several hundred million dollars in sales, but it remains a figure published by the buyer: it says nothing about the brand’s profitability or customer loyalty.<\/p>\n When a physician or practitioner recommends a routine, the purchase no longer rests on a promotion, an influencer or a recommendation algorithm. The patient’s trust transfers to the brand, and that trust is renewed at every appointment. In our reading, this explains the interest of a group already established in dermatology: acquiring a brand whose customers come back regularly and which sells on the basis of expert advice, and therefore depends less on the promotional cycles that now weigh on the margins of many beauty brands. This reading is an analysis, not a published fact: neither Galderma nor the sellers have disclosed a repurchase rate.<\/p>\n A second mechanism works in favour of this model: the complementarity between the procedure and at-home care. A treatment in the practice creates an immediate need, to prepare the skin and then extend the result, and the range dispensed by the practitioner meets that need at the right moment. Distribution is also controlled: the brand knows who sells its products, at what price and with what message. Here is what a brand creator can take from this deal, whatever their original sector:<\/p>\n These four levers can be measured, and that is what an investor looks at: the number of active accounts, the average basket per practitioner, the share of recurring sales, the dependence on a few large distributors. A brand that does not track these indicators will struggle to demonstrate its value on the day it seeks financing, a partner or an acquirer. Setting up a simple dashboard from the first sales is a modest investment, and it avoids rebuilding the history in a hurry during a negotiation.<\/p>\n If you work as a physician, surgeon or aesthetic medicine practitioner, or if you run an institute, a spa or a wellness venue, Galderma’s deal raises a simple question: do your clients not already follow you for your recommendations? Many professionals advise products from other brands without earning either recurring revenue or control over the experience. Creating your own range lets you extend care at home with a formula that reflects your protocol, a message consistent with your practice, and a brand that carries your signature. This path already exists in the market, with very uneven results depending on product quality, clarity of the offer and the ability to train the teams who present it.<\/p>\n This project does, however, change the nature of your business. You become a manufacturer or a person placing a cosmetic product on the market, with obligations of your own. In the European Union, Regulation (EC) No 1223\/2009 requires a Responsible Person, a safety assessment and a PIF (Product Information File) kept available for the authorities for each product. Claims must remain those of a cosmetic: messaging that is too close to the medical moves the product into another category. To understand the applicable framework, Clear’s page on cosmetic regulations<\/a> gives a first overview.<\/p>\n Before you start, ask yourself a few fundamental questions. They are more useful than a general market study, because they force you to look at your business as it is:<\/p>\n These answers determine the budget, the timeline and the choice of manufacturer. A range of three or four consistent references, backed by a real protocol, is far more likely to convince than a broad catalogue launched without clear positioning.<\/p>\n The first is to stay in the practice. The brand keeps full control of its message and distribution, but its growth depends on the number of practitioners it manages to train and retain, which limits its pace. The second path opens other channels: e-commerce, institutes, selective distribution or export. It brings volume, but it creates channel conflict if prices and messaging diverge from one point of sale to another, and it exposes the brand more to promotions. The third is to be backed by a group, as ZO illustrates: the acquirer funds growth, but the founder gives up control of the trajectory.<\/p>\n At Clear, an EU \/ UK \/ US cosmetic regulatory compliance firm, we see these three paths from the inside, because each one tests the product file. A brand that sells only in practices may, without knowing it, accumulate approximations: undocumented claims, labelling that differs from one market to another, formulas changed without updating the file. These gaps become visible as soon as a distributor or an acquirer reads the file closely. This is why regulatory due diligence in mergers and acquisitions<\/a> examines product compliance before signing, and why a brand preparing its growth benefits from addressing this issue well in advance.<\/p>\n A single deal does not make a trend. The agreement announced on 14 October 2026 is not yet completed and depends on decisions by outside authorities, and the figures cited come from the acquirer’s press release. It would be unwise to conclude that every brand born in a practice will be worth a high multiple of its sales. ZO built a network of more than 16,500 accounts over nearly twenty years of existence, a base that few young brands can hope to replicate quickly. The model rests on the practitioner’s credibility, which is built over time and can erode if the product disappoints.<\/p>\n It should finally be recalled that the timetable of this kind of transaction remains uncertain. Between signing and closing, the relevant authorities review the file, conditions may change, and integrating a brand into a large group plays out over several years. The effects on ZO’s partner practitioners, on their commercial terms or on the brand’s identity are, at this stage, neither announced nor assessable. It is better to follow Galderma’s official communications than to rely on interpretations circulating on social networks.<\/p>\n For an executive or a creator, the most useful lesson is therefore methodological: before drawing inspiration from an acquisition, one must distinguish what is published fact, estimate and interpretation. One must also check that one’s own brand has the assets that make the model transferable: a reference professional, a consistent range, controlled distribution, a solid regulatory file. The marketing and distribution challenges of the cosmetics industry<\/a> are often decided on these organisational details, which are less visible than deal values.<\/p>\n In short:<\/strong> by announcing on 14 October 2026 the acquisition of ZO Skin Health for USD 1.5 billion, Galderma confirms that physician-dispensed skincare is a channel capable of interesting a large group. For a practitioner, an institute or a wellness brand, creating a range is feasible if one accepts the obligations of a company placing a cosmetic product on the market. For an established brand, the strength of the product file conditions growth as much as resale value.<\/p>\nWhy a professional channel attracts so many acquirers<\/h2>\n
\n
Practitioner, institute or spa: what if your expertise became a range?<\/h2>\n
\n
Three possible paths for a brand born in a practice<\/h2>\n
What this acquisition does not prove<\/h2>\n